Эпизоды
-
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Daniel Lewi, co-founder and CEO of the CATS Foundation, about the world of rare disease advocacy. Dan shares his personal journey as a patient advocate and discusses the mission of the CATS Foundation, which focuses on raising awareness and driving research for Tay-Sachs and Sandhoff disease. He highlights the importance of collaboration and transparency in advocating for better treatment options, emphasising the need for data sharing, especially in drug repurposing efforts. Dan also shares insights into engaging with pharmaceutical companies, emphasising the importance of building trust, clear communication, and collaborative strategies. Throughout the conversation, the critical role of patient voices, diverse perspectives, and community involvement in shaping advocacy efforts is emphasised, ensuring that the needs and experiences of individuals impacted by rare diseases are at the forefront of research and development initiatives.
Dan Lewi’s eldest daughter Amelie was diagnosed with Tay-Sachs in 2011 at 15 months of age and upon finding that there was no dedicated advocacy group providing support for families affected by this disease in the UK he set set-up the Cure & Action for Tay-Sachs (CATS) Foundation with his wife Patricia. Since the group was launched, they have been able to grow The CATS Foundation so that it now offers a variety of services to its family members and has been actively involved in the research investigating therapeutic treatments for Tay-Sachs and Sandhoff disease. In addition to this, Dan is the one of the founding members and Chairman of the European Tay-Sachs and Sandhoff Charity Consortium which brings together all the European patient groups leading the fight against the diseases and is part of the team establishing the IGGA, a global organisation bringing together all the advocacy groups for GM1 and GM2. Dan is fully committed to leading the charity towards its goal of finding a treatment so that there is hope for those families affected by Tay-Sachs and Sandhoff in the future
Other relevant references | Outras referências relevantes:
CATS Foundation (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Cristina Fraga, CEO da mindout, uma Health Startup focada na saúde mental. Nesta conversa, a Cristina partilha a sua transição do mundo corporativo para o empreendedorismo, discutindo a importância do tema da saúde mental nas empresas e na sociedade. Exploramos o impacto do Burnout, a sua prevalência global e consequências económicas, bem como estratégias para identificar e mitigar esta condição nas organizações. Além disso, abordamos desafios na implementação de programas de prevenção, a importância da liderança na quebra do estigma e como a tecnologia pode ser utilizada para melhorar a saúde mental dos colaboradores, especialmente no contexto do trabalho remoto. Por fim, discutimos a relevância de fornecer suporte e ferramentas para estudantes universitários lidarem com estas questões.
Cristina Fraga é Fundadora e CEO da mindout, uma health/brain-tech startup sediada em Lisboa, que opera na área da saúde mental e está disponível para estudantes universitários, trabalhadores e empresas e profissionais de saúde de todo o mundo. Cristina é Engenheira Informática do IST, trabalhou 8 anos na Deloitte, 2 anos na Deloitte PT e 6 anos na Deloitte US nos escritórios de San Francisco e Manhattan, sempre na área da Tecnologia. Voltou para Portugal em 2013 onde esteve 8 anos na EDP, também ligada ao Digital e Marketing Digital. Em 2020 tirou um Executive MBA no INSEAD e juntou-se à Liberty Insurance como Chief Marketing Officer da Europa. Como sempre teve vontade de criar valor na área da saúde, após a saída de um burnout em 2022, decidiu criar a mindout, utilizando a experiência que viveu nessa mesma jornada, o know-how de business management e liderança com o seu lado tecnológico, para criar uma solução escalável e sustentável para prevenção e reversão de burnouts com uma jornada clara e transparente, com grande foco em Inteligência Artificial.
Other relevant references | Outras referências relevantes:
mindout (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisódio editado por João Cunha Studios
-
Пропущенные эпизоды?
-
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha explore the intersections of technology, healthcare, and leadership with Alan Triggs, Chief Digital Officer for Nokia. They delve into the impact of AI on industries, discussing the evolution of AI, its role in job creation and displacement, and its potential impact on healthcare and education. Alan shares insights on data management, privacy concerns, and the role of regulation in technology. The discussion extends to the personal experiences, touching on longevity, wellness, and the importance of sleep hygiene in the digital age. Alan also shares experiences from relocating to Portugal and Nokia’s investment in the country. Tune in to explore these topics and more in this insightful episode.
Alan Triggs is the Chief Digital Officer for Nokia globally, with responsibility for Nokia’s information technology (IT) and digitalisation initiatives. In this role, he is responsible for the global infrastructure for enterprise computing, networking, and end-user services, and enterprise applications covering R&D, services, supply, and financial & commercial systems. He is responsible for number of digital transformation initiatives including a company-wide cloud transformation, the modernisation of core application systems, and the corporate data strategy. Alan has held a number of leadership roles in IT; Telecom and has lived and worked in in seven countries across Africa, Europe and the US. He is currently based out of Portugal.
Other relevant references | Outras referências relevantes:
Blueprint (by Bryan Johnson)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast CruzamentoEpisode edited by João Cunha Studios
-
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha dialogam com Luís Oliveira, Senior Associate Director Research Programs na The Michael J. Fox Foundation, abordando a missão inspiradora da fundação, o impacto global das doenças neurodegenerativas em saúde e economia, e estratégias eficazes para mitigar riscos na Doença de Parkinson.
Luis Miguel Oliveira is a Senior Associate Director of Research Programs at The Michael J. Fox Foundation and the Founder of v-ATPase Alliance for rare diseases due to v-ATPase defects.
Luís is an expert in the field of Parkinson’s disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets in Parkinson’s disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of the v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities to further advance therapeutic development.
With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures.
Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson’s disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson’s research and drug development fields by enabling an objective characterization of the disease based on its biological features.
Luis Miguel Oliveira’s educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York.
Other relevant references | Outras referências relevantes:
v-ATPase Alliance (website) The Michael J. Fox Foundation (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Stefan Buttigieg, about the impact of AI on healthcare. Highlights include AI’s potential in public health, data sharing challenges in Europe, AI projects in Malta, and the importance of equity and ethical data handling in healthcare.
Dr. Stefan Buttigieg is a Specialist in Public Health Medicine working in the Ministry for Health in Malta !🇲🇹 He is a Keynote Speaker with 50+ public speaking engagements track record and an avid content creator!📱🎙️. He is the manager of the National Contact Point of eHealth and lectures at the University of Malta on the topics of Digital Health, Social Media in Healthcare and Digital Therapeutics. He is the Vice-President of the EUPHA Section on Digital Health and is a WFPHA Governing Council Member. Dr Buttigieg is on a mission to enable equitable Digital Health and Health Data for All ensuring that no one is left behind
Other relevant references | Outras referências relevantes:
Stefan Buttigieg (Website) Yuval Noah Harari argues that AI has hacked the operating system of human civilisation Yuval Noah Harari at the Frontiers Forum - AI and the future of humanityContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia and Daniel Guedelha talked with Ana França and António Gonçalves. They delve into Health, Technology, and Sustainability, with a focus on transplantation, common transplant types and their impact, insights from companies expanding globally, and future trends in transplantation technology. The discussion showcases TransplantHUB’s role in harnessing these advancements for patient benefit.
Meet Ana França, a highly skilled and dedicated organ donation and transplantation management expert. With over a decade of experience, Ana has been instrumental in transforming Portugal’s organ donation and transplantation system, improving patient outcomes, and increasing access to life-saving procedures for those in need. Her global initiatives in developing digital transplantation registries have revolutionized how organ donation and transplantation procedures are managed worldwide, earning her recognition as a leader in her field. Ana’s expertise in organ donation and transplantation and her passion for improving patient outcomes make her an invaluable asset to managing organ donation and transplantation.
With over 25 years of experience in IT Services, António Gonçalves brings together a vast experience in business analysis with a comprehensive technical area know-how in diverse industries, including Healthcare, Insurance, Local Government, Industry, and Logistics. This experience, and above all, the unquestionable ability to apply it in various sectors, allowed him not only to create reasonable conceptual solutions but, above all, practical solutions amenable to a linear technical implementation. His adaptability to a diverse audience, both functional and technical, has allowed him to design innovative products and, more importantly, create practical, innovative solutions with a linear technical implementation.
Other relevant references | Outras referências relevantes:
Transplant Hub (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Patrícia Calado sobre estratégias de inovação e pesquisa na saúde, bem como a necessidade de avaliar adequadamente os investimentos públicos nesta área. A interdisciplinaridade na pesquisa médica é também destacada como crucial para solucionar problemas complexos de saúde.
Patrícia Calado is a results-driven professional dedicated to accelerating positive impact through the uptake of innovation into healthcare. Her career was built on collaborative work with healthcare institutions, industry, and research organizations all over the country. Currently she’s a member of the Board at NOVA Medical School (NMS), as Vice-Dean for Research, and she’s responsible for developing and implementing the faculty’s research and innovation strategy, in close articulation to the Dean.
Previously she worked for different innovation and funding agencies in Portugal as the National Contact Point and Delegate for Health in the EU Research and Innovation Programme (2015–2022). Between 2020 and 2022 she was a member of the Board at the Agency for Clinical Research and Biomedical Innovation (AICIB), were she led the international strategy of the Agency and set up the team of National Contact Points and Delegates for Health.
She has 25+ years of experience in the fields of Health and Life Sciences with experience in the coordination of multi-disciplinary teams in the context of academia, SME, and governmental agencies.
She’s driven by inspiring and motivating people to achieve a shared vision and goals. During her career she implemented processes of transformational leadership by encouraging innovation and empowering her teams to take risks and learn from mistakes, while creating a culture of trust, openness, and learning in the organization.
She has a PhD in Biomedical Sciences from the Faculty of Medicine of the University of Lisbon and a degree in Biology from the Faculty of Sciences and Technology of the University of Coimbra.
Other relevant references | Outras referências relevantes:
NOVA Medical School (NMS) (website) Agency for Clinical Research and Biomedical Innovation (AICIB) (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Ron DePinho who delves into his contributions to cancer research and innovation, emphasizing the transformative potential of biotechnology in this critical field. His work is dedicated to advancing our understanding of cancer biology, enabling the development of more precise diagnostic tools and targeted therapies. Through his efforts, he aims to revolutionize the way we approach cancer treatment, with the ultimate goal of improving patient outcomes and quality of life. Additionally, Ron de Pinho actively engages in educating influential figures such as the President of the United States and the Pope, advocating for policies that support the advancement of biotechnology in healthcare and sustainability. His dedication to both research and advocacy solidifies his position as a leading figure in the biotech industry.
Ronald A. DePinho, M.D. is currently past president and distinguished university professor of The University of Texas MD Anderson Cancer Center. His research has focused on the fundamental mechanisms driving cancer and aging and the clinical application of such knowledge to prevent and treat disease.
Dr. DePinho studied biology at Fordham University, where he graduated class salutatorian, and received his M.D. degree with distinction in microbiology and immunology from the Albert Einstein College of Medicine. He performed his residency and postdoctoral training at Columbia-Presbyterian Medical Center.
Dr. DePinho’s independent career began at Einstein as the Feinberg Senior Faculty Scholar in Cancer Research and an ACS Research Professor. He then joined the Dana-Farber Cancer Institute and Harvard Medical School where he was the founding Director of the Belfer Institute for Applied Cancer Science and a Professor of Medicine and Genetics at Harvard. As president of MD Anderson, Dr. DePinho conceived and launched the Moon Shots Program, a goal-oriented comprehensive effort designed to accelerate declines in cancer incidence and mortality. This initiative has yielded practice-changing advances in cancer and inspired the national cancer moonshot under President Biden. He also elevated MD Anderson’s research and graduate programs, recruited many world class faculty including National Academy Members and its first Nobel Prize. To improve cancer care beyond MD Anderson, he launched and assembled a network of cancer institutions in 24 countries, reaching one-third of the human population.
As a researcher, he has published over 400 articles, books and chapters that have advanced our understanding of cancer, aging and degenerative disorders which have led to clinical advances including new cancer drugs and diagnostics. His most notable discoveries include elucidation of the core molecular pathway for aging, determination of the basis for the intimate link between advancing age and increased epithelial cancer incidence, establishment of the central role of telomeres in cancer genome instability, discovery of Sin3 and linkage of sequence specific transcription factors and chromatin regulators, demonstration that aging itself can be reversed which led to new therapeutic strategies for aging and age-related diseases including Alzheimer’s Disease. To translate these basic discoveries, he founded 9 private and publicly traded biotechnology companies and served as an advisor or director for biotech and large biopharma companies focused on oncology. His public service includes advisory and directorship roles for AACR and the NIH, as well as the Vatican and several countries. He is chairman and co-founder a non-profit, OPA Health (previously, Unite to Prevent Cancer) whose mission is disease prevention in underserved communities. As an advocate, he was a key instigator in the bipartisan bill raising the age of tobacco purchase to 21 (T21) and the bipartisan Cures Act. He is Vice Chair of the BOD for Act For NIH, a non-profit advocacy organization to garner bipartisan support for the NIH resulting in an additional $14.9B to the base budget and restoring the NIH budget following years of inflationary decline.
For his fundamental contributions to cancer and aging and to healthcare, he has been recognized with numerous honors and awards. He was named one of the 100 most influential healthcare leaders, according to Modern Healthcare. His honors include the Melini Award for Biomedical Excellence, the American Society for Clinical Investigation Award, the Biomedicum Helsinki Medal, Albert Szent-Györgyi Prize, AACR Clowes Award, American-Italian Foundation Prize, among others. He is a member of the National Academy of Medicine and the National Academy of Science, and a fellow of the American Academy of Arts and Sciences, the American Association of the Advancement of Science and the American Association of Cancer Research. He received Fordham University’s McMahon Memorial Award for Distinguished Public Service, honorary degrees from Harvard University and Hofstra University, and the Ellis Island Medal of Honor. For his work to improve the health of Portugal’s people, Dr. DePinho was recognized by its president with the highest commendation, the Order of Saint James of the Sword.
Other relevant references | Outras referências relevantes:
Ron DePinho (website) Lynda Chin (website) MD Anderson Cancer Center (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Katrien Buys about her experiences in the AXA and Ageas merger, highlighting the challenges faced and the strategies that led to success. She also discussed Impact Investing, a concept that stirs controversy among traditional investors, drawing from her role at the Ageas Foundation. Katrien’s inspiring take on Innovation and the Role of Failure underscores how failures can drive progress, backed by compelling examples. This interview offers a profound exploration of these crucial topics that resonate universally.
Katrien Buys was born and raised in Belgium, and a mathematician by education at the Catholic University of Leuven (KU Leuven Belgium). This degree led her to start in the insurance industry where she worked in the Belgian entity of the group during several years. Triggered by a need of exploring the business world beyond its boundaries, a guiding principle that she keeps valid until today, she set off in 2012 to join the Italian operations and have her first international working experience. After a return to Belgium for 2 years, leading a strategic transformation program, she took the bigger opportunity of travelling and moving with her family to Portugal. Katrien bridges the gap between her work at Ageas Portugal and impact organizations, creating new business opportunities for positive societal impact. She likes to be innovative and to always find ways to cooperate in different areas, creating value both for these organizations and for Ageas Portugal. More importantly, she asks questions regularly, most often “why?” which is the most powerful question to keep you on track and ensure you don’t take anything for granted. Because she works in strategy, innovation and sustainability, she sees her role as bringing people together, having good conversations and co-creating a world of hope for as many people as possible. In the spirit of Ageas Portugal’s mission to deliver emotional and meaningful experiences in people’s lives, there is the vision that, with radical collaboration, we can be a welcome presence in every Portuguese household. Katrien is the winner of the 2021 MAZE Runner Award.
Other relevant references | Outras referências relevantes:
Impact Investing Explained: Definition, Types, and Examples Podcast Cruzamento #65: Gabrielle Fitzgerald: Philanthropy, a platform for social change Podcast Cruzamento #71: Carlos Oliveira: Qual o impacto das Fundações no ecossistema?Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Carlos Oliveira que partilha a sua opinião sobre o papel das fundações no ecossistema da Saúde e Tecnologia em Portugal, e como podem ajudar a impulsionar o desenvolvimento destes setores. Falámos também sobre o foco que Braga coloca nas áreas da Tecnologia e Saúde e, os principais resultados alcançados.
Carlos Oliveira é cofundador e Presidente Executivo da Fundação José Neves. Com um percurso ligado à economia, à inovação e ao empreendedorismo, ocupou o cargo de Secretário de Estado do Empreendedorismo, Competitividade e Inovação, no XIX Governo Constitucional. Foi também conselheiro do Conselho Europeu de Inovação (EIC), entre 2016 e 2021, sendo o único representante português. Criou aos 22 anos, a sua primeira empresa, a MobiComp, que seria adquirida pela Microsoft em 2008. É um empreendedor em série, tendo co-fundado e investido em diversas startups como a Automaise, iMobileMagic, Asap54, PeekMed, Cardmobili, entre outras. Foi condecorado pelo Presidente da República Jorge Sampaio como Oficial da Ordem de Mérito.
Other relevant references | Outras referências relevantes:
Podcast Cruzamento #70: Mark Hamill: How to find your advisory board? Podcast Cruzamento #65: Gabrielle Fitzgerald: Philanthropy, a platform for social change Podcast Cruzamento #47: Pedro Gouveia: Fundação Champalimaud, Um Centro para o Desconhecido Podcast Cruzamento #41: João Pedro Ribeiro (PeekMed): A Sustentabilidade É Uma Preocupação Das Startups? Podcast Cruzamento #25: André Eiras dos Santos e a Scaleup de Saúde DigitalContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Mark Hamill to unpack the world of advisory boards, where insatiable curiosity is a driving force, and to discover how these boards contribute to shaping the landscape of innovation and change.
Mark Hamill is a thought leader in talent acquisition focused on C-suite roles, CEO succession, and Board development. He represents Ackermann International as NED, serves as YPO UK chapter chair, and is CEO of his own company, The Naked Headhunter. He also co-founded the Virtual Advisory Board (VAB). Mark is passionate about people and loves connecting CEOs to Board talent who can help solve problems. He believes that building your professional network is the best way to find your next role. Mark builds boards both in the real world and for the Metaverse. He is firmly committed to CEO Fitness and the collaborative work of Transition Tribes.
Other relevant references | Outras referências relevantes:
Virtual Advisory Board (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Beatriz Isabel Cruzeiro, aluna de Engenharia Biomédica, que nos fala sobre a importância desta Engenharia no cruzamento da Saúde, Tecnologia e Sustentabilidade e, sobre como está a moldar o futuro nestas áreas cruciais para o nosso bem estar.
Beatriz Cruzeiro é estudante de Mestrado de Engenharia Biomédica na Universidade de Aveiro, com particular interesse e especialização na área de Física Médica. Atualmente encontra-se a dar os primeiros passos no que será a sua tese de mestrado, que consistirá no desenvolvimento de uma nova dosimetria FLASH para terapia de feixes de protões através da avaliação do fluxo de neutrões no Centro Alemão de Investigação do Cancro (DKFZ), em Heidelberg. No seu projeto de licenciatura trabalhou com a aplicação de Redes Neuronais Artificiais para processamento de sinal em Sistemas de Tomografia por Emissão de Positrões, no laboratório associado de Deteção de Radiação e Imagem Médica do I3N-Aveiro da Universidade de Aveiro. Após isto, recebeu uma bolsa de investigação no mesmo laboratório para continuar esta investigação e submeteu o trabalho na 2022 IEEE Nuclear Science Symposium, Medical Imaging Conference and Room Temperature Semiconductor Detector Conference em Milão, Itália. Atualmente, o desenrolar deste trabalho encontra-se aceite para a edição de 2023 da mesma conferência. No verão de 2022 realizou um estágio na empresa Innowave, onde trabalhou como Data Scientist no produto da ViGIE Solutions, que oferece uma plataforma de cuidados de saúde que integra inteligência artificial em sensores especializados. Quanto ao associativismo, entrou para a equipa da Associação Nacional de Estudantes de Engenharia Biomédica em 2020 no Departamento de Comunicação e Multimédia, sendo que em 2021 passou a desempenhar o cargo de Diretora desta mesma divisão, onde exerceu funções até 2022. Foi também Coordenadora do setor de Comunicação e Multimédia da segunda edição do Biomedical Engineering Summit em 2021 e foi parte da comissão organizadora e fundadora do evento Biomedical Future. Posteriormente integrou a direção do XVIII Encontro Nacional de Estudantes de Engenharia Biomédica na Universidade de Aveiro no departamento de Comunicação e Imagem. Atualmente, é membro da equipa do Podcast Cruzamento, que visa cruzar os temas da tecnologia, saúde e sustentabilidade.
Other relevant references | Outras referências relevantes:
Podcast Cruzamento # 64: Walter Greenleaf: Translating neuroscience with VR (EN) Podcast Cruzamento # 61: Albert “Skip” Rizzo: Democratising Virtual Reality (EN)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com José Paulo Carvalho (Hope Care) sobre o papel da tecnologia nos cuidados médicos em casa, a abordagem única da Hope Care em relação à inteligência artificial, e como enfrentam as preocupações com a qualidade e segurança dos doentes. É um episódio que certamente marcará a sua perspectiva sobre o futuro dos cuidados de saúde!
José Paulo Carvalho é fundador e CEO da Hope Care SA com larga experiência na área da saúde digital. Durante 10 anos, foi gestor de uma Organização Sem Fins Lucrativos Portuguesa, onde coordenou equipas de integração social e projetos de telecuidado. Além disso, trabalhou como consultor em Sistemas de Informação na Universidade Católica Portuguesa e na Direcção Geral do Património do Ministério das Finanças. Durante a sua carreira, desenvolveu e monitorizou cerca de 75 projetos em Sistemas de Gestão da Qualidade em Saúde e Organizações Sociais. Em 2011, criou um projeto de saúde digital e fundou a empresa Hope Care em 2012. A Hope Care é uma fornecedora líder em serviços de saúde digitais (m-Health), implementando vários projetos diferentes na Europa. José Paulo Carvalho é apaixonado pelo design e implementação de serviços conectados em casa, desenvolvendo o conceito Hospital@Home. Em termos académicos, possui uma licenciatura em Teologia pela Universidade Católica Portuguesa, é especialista em Ciências Documentais pela Universidade de Lisboa e possui um MBA Executivo pela AESE/IESE.
Other relevant references | Outras referências relevantes:
Hope Care (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Sofia Ferreira, uma líder inspiradora no campo da saúde feminina, sobre um tema de extrema importância e central na luta contra a desigualdade: investir na saúde da mulher. Falámos também sobre o papel revolucionário dos DAOs (Organizações Autónomas Descentralizadas) na área da saúde.
Vamos fazer da saúde feminina uma prioridade e promover a igualdade de acesso aos cuidados de saúde. Juntos, podemos fazer a diferença!
Sofia Ferreira is the new Managing Director of Organon Portugal. She is a pharmacist by training with a degree marketing and an MBA. Sofia started her career in Schering-Plough where she worked for 10 years in roles with increasing responsibilities. Upon the acquisition of Schering-Plough, she has moved to MSD, where she held multiple roles of increasing responsibility, including people manager roles, in different therapeutic areas, from WH, to Established Brands, Vaccines and Hospital Specialties After 10 years, she has decided to change and joined Organon in Portugal as Marketing and Sales Director, managing a broad portfolio of products. She is an invited teacher in AESE, one of the most important business schools in Portugal, giving lectures on pharmaceutical industry marketing and communication. She is also an active member of Women Leadership groups and is an invited guest to podcasts and conferences on the topic. Outside of work, Sofia is happily married to João and they have 2 children, Rodrigo with 16 years old and Vicente with 10 years old.
Other relevant references | Outras referências relevantes:
Organon, here for her health Organon: Jobs Athena DAO Podcast Cruzamento #05: Inês Santos Silva e o Empreendedorismo no Feminino Podcast Cruzamento #59: "Nelson Jordan: Does DAO (Decentralised Autonomous Organisation) ring a bell?Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Luís Lobo Jordão sobre o que é isto de atingir a liberdade financeira e como pode o movimento F.I.R.E. contribuir para este objectivo e, como escolher investimentos sustentáveis nas áreas da saúde e tecnologia. Deixam também uma dica para o melhor investimento de todos. Sabe qual é?
Luís Lobo Jordão é um profissional de investimentos com mais de 20 anos de experiência. Especialista em investimento em acções, factor investing e planeamento financeiro para a reforma.
Tendo iniciado a actividade na CGD - onde criou o maior fundo português de acções - o Luís colabora desde 2016 com a SGF no desenvolvimento e gestão de carteiras sob a marca @Stoik, nomeadamente o PPR SGF Stoik e o FPA SGF Reforma Stoik.
É também dinamizador de várias iniciativas dedicadas à literacia financeira, entre as quais o grupo de Facebook / Podcast “FIRE Talks Portugal”, com muito conteúdo ligado a FIRE (Financial Independence, Retire Early), onde ajuda, ao longo de vários episódios, milhares de pessoas a melhor compreenderem a área financeira e a tomarem melhores decisões de investimento.
Licenciado em Economia, pela Nova School of Business and Economics (1999) e Direito, pela Faculdade de Direito de Lisboa (2017). Pós-graduado em Direito da Economia e do Investimento Social (2017). Chartered Financial Analyst pelo CFA Institute (2009). Detém ainda o Certificate in ESG Investing pelo CFA UK (2021).
Other relevant references | Outras referências relevantes:
Podcast FireTalks Portugal (Youtube) Podcast FireTalks Portugal (Spotify) Go Parity (link afiliado) Impacto: porque queremos contribuir (stoik.pt)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Gabrielle Fitzgerald about the significance of strong leadership and the power of optimism in addressing the interconnected crises our world is facing.
Gabrielle Fitzgerald is the founder and CEO of Panorama and co-founder of Pandemic Action Network. With decades of experience in politics, policy, and philanthropy, Gabrielle has become a recognized voice and thought leader on catalytic philanthropy, women’s leadership, and pandemic preparedness and response. As a platform for social change, Panorama’s mission is to maximize social impact by partnering with visionary leaders to co-develop solutions with audacious thinking and bold action. Since its founding, Panorama has brought much-needed attention and funding to complex challenges including pandemic preparedness, gender parity in politics, and adolescent mental health. Gabrielle also co-founded the Pandemic Action Network, a partnership of over 250 diverse organizations aligned in a belief that every effort made in the fight against COVID-19 should leave a long-term legacy - one where humanity is better prepared to deal with outbreaks and prevent a deadly and costly pandemic from happening again. Prior to founding Panorama, Gabrielle spent more than a decade working in philanthropy. She directed the $100M Ebola Program at the Paul G. Allen Family Foundation and served as the director of Global Program Advocacy at the Bill & Melinda Gates Foundation. Gabrielle spent the early stage of her career in Washington, D.C. She led the public affairs strategy for HIV/AIDS at the U.S. Agency for International Development and served as the communications director for the U.S. Committee for Refugees. She also served as a speechwriter for President Clinton at The White House. Gabrielle is board president of American Friends of United for Global Mental Health. She holds an M.A. from the Maxwell School at Syracuse University and a B.A. from American University.
Other relevant references | Outras referências relevantes:
Panorama Global (website) Tomorrow Now (website) Bill & Melinda Gates Foundation (website)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Walter Greenleaf, an expert in the field of virtual reality (VR) and its transformative impact on healthcare. Also, we dove into ecosystem use cases and how fun VR is becoming.
Walter Greenleaf PhD. is a neuroscientist and a medical technology developer working at Stanford University. With over 35 years of work focused on developing clinical applications of medical virtual reality technology, Walter is considered a leading authority. Walter is currently a Visiting Scholar at Stanford University’s Virtual Human Interaction Lab. He also works to develop next-generation wearable sensors as part of the eWear Program at the Stanford School of Engineering. He previously served as the Director of the Mind Division, at the Stanford Center on Longevity, where his focus was on age-related changes in cognition.
Walter was the founding Chief Science Officer for Pear Therapeutics and is the Chief Science Officer for Interaxon.
In addition to his academic work, Walter is the technology and neuroscience advisor to several early-stage medical product companies and accelerator/incubator programs.Other relevant references | Outras referências relevantes:
Virtuleap International Virtual Reality Healthcare Association Virtual Human Interaction Lab (Stanford University)Contacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Eyal Zimlichman about the hospital of the future, a world where healthcare doesn’t have an address, and the emerging field of multiomics, which involves analyzing multiple layers of biological information to tailor treatments to individual patients.
Prof. Eyal Zimlichman is an internal medicine physician, a health care executive and a researcher focused on assessing and improving health care quality and value, patient engagement and patient safety. Prof. Zimlichman currently serves as Chief Transformation Officer and Chief Innovation Officer at Sheba Medical Center, Israel’s largest hospital. In this position he oversees the transformation efforts carried out at the Medical Center as it aims to redesign healthcare to be focused on patients, while being more effective, efficient and equitable. For these reasons, Prof. Zimlichman founded Sheba’s global innovation program (ARC – Accelerate, Redesign and Collaborate). Prior to this Prof. Zimlichman held the position of Chief Medical Officer and before that as Chief Quality Officer, both at Sheba. Preceding his work at Sheba, Prof. Zimlichman held the position of Lead Researcher at Partners Health Care Clinical Affairs Department in Boston where he was involved in the efforts to bring about a strategic care redesign initiative. In that capacity, Prof. Zimlichman established their program for collecting and reporting patient reported outcomes across the continuum of care, a program that earned international appraisal. During that time, Prof. Zimlichman held an appointment at Brigham and Women’s Hospital and Harvard Medical School affiliated Center for Patient Safety Research and Practice, where he conducted research on implementing technology to improve quality and patient safety. Prof. Zimlichman is a founding member of the International Academy of Quality and Safety in Health Care and an International Expert at the International Society of Quality in Healthcare (ISQua). He also served as an advisor to the Office of the National Coordinator for Health Information Technology in the U.S. Department of Health and Human Services. In 2007 Prof. Zimlichman was selected as a member of Sheba’s Talpiot Medical Leadership Program, a program aimed at advancing the brightest young physicians into leadership roles. In 2017 he was appointed head of the program. Prof. Zimlichman is a graduate of the Harvard School of Public Health Master of Science in Healthcare Management program and has earned his MD at the Technion Israel Institute of Technology.
Other relevant references | Outras referências relevantes:
Sheba Tel HaShomer City of HealthContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Andrew Shipilov about strategy in healthcare and technology, the different levels of cooperation between large organisations and startups in various countries, and the symbiosis between humans and machines.
Andrew Shipilov is a Professor of Strategy and the John H Loudon Chair of International Management at INSEAD. He is an expert in the areas of strategy, innovation, and networks. His current academic research examines how social networks, strategic alliances, and ecosystems affect firm’s competitive advantage.
Other relevant references | Outras referências relevantes:
INSEAD: Andrew Shipilov Book: Network Advantage: How to Unlock Value From Your Alliances and Partnerships (Andrew Shipilov) Study: European corporates choose to innovate with startups as the global economic slowdown downturn weighs on their budgetsContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento -
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Albert ‘Skip’ Rizzo about how Virtual Reality (VR) can change education and mental health care, and its limitations and pitfalls.
Albert ‘Skip’ Rizzo is a clinical psychologist and Director of Medical Virtual Reality at the University of Southern California Institute for Creative Technologies. He is also a Research Professor with the USC Dept. of Psychiatry and at the USC Davis School of Gerontology. His career began as a clinician providing rehabilitative services for persons with traumatic brain injuries and stroke. Over the last 25 years, Skip has conducted research on the design, development and evaluation of Virtual Reality systems targeting the areas of clinical assessment, treatment and rehabilitation across the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. This work has focused on PTSD, TBI, Autism, ADHD, Alzheimer’s disease, stroke and other clinical conditions. Some of his recent work has involved the creation of intelligent virtual human (VH) patients that novice clinicians can use to practice skills required for challenging diagnostic interviews. He has also developed VHs for use as online/mobile virtual human healthcare guides and as clinical interviewers with automated sensing of facial, gestural, and vocal behaviors useful for inferring the state of the user interacting with these virtual human entities. In spite of the diversity of these clinical R&D areas, the common thread that drives all of his work with digital technologies involves the study of how interactive and immersive Virtual Reality simulations can be usefully applied to address human healthcare needs beyond what is possible with traditional 20th Century tools and methods. To view some videos of this work, please visit this YouTube channel
Other relevant references | Outras referências relevantes:
Albert ‘Skip’ Rizzo: YouTubeContacts | Contactos:
CruzamentoPodcast.com [email protected] LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento Instagram: @cruzamentopodcast YouTube: Podcast Cruzamento - Показать больше
![80: Dan Lewi: Rare Disease Advocacy - Trust and Transparency in Action [EN]](https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/91/38/d9/9138d920-1a8b-c96e-4f46-8e65dbadd6ed/mza_9737997980080240958.jpg/80x80bb.jpg)